Evidence record · ER-GONADORELIN-DIAG-029
Can gonadorelin test pituitary gonadotrophin response?
Authorised gonadorelin evokes LH and FSH responses for specialist diagnostic pituitary testing
Authorised gonadorelin can evoke luteinising-hormone and follicle-stimulating-hormone responses for specialist diagnostic testing of pituitary gonadotrophin function. The UK product information supports that narrow diagnostic use. It does not support bodybuilding, fertility self-treatment, long-term hormone optimisation or an unverified gonadorelin vial.
Claim boundary
What this verdict covers
The supported claim is a supervised diagnostic challenge using the authorised medicine and timed laboratory measurements. It is not a treatment or performance claim.
- Compound
- Gonadorelin
- Population
- Patients undergoing specialist diagnostic assessment
- Outcome
- Luteinising-hormone and follicle-stimulating-hormone response
- Record ID
- ER-GONADORELIN-DIAG-029
Evidence synthesis
What the research can support
The UK Summary of Product Characteristics defines gonadorelin’s diagnostic indication, administration setting, interpretation and safety information. This regulatory evidence directly supports the test within its labelled context.
Why the confidence is high
A diagnostic response must be interpreted with clinical history and assay timing. The authorised product evidence cannot verify a different source, presentation or use.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-GONADORELIN-DIAG-029 addresses one bounded question: Can gonadorelin test pituitary gonadotrophin response?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Authorised medicine and clinical use, the verdict is Supported and confidence is High. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| Gonadorelin UK Summary of Product Characteristics | The SmPC defines the authorised diagnostic use, population and safety conditions. | It does not support self-treatment or an unverified vial. | 10 August 2026 |
| MHRA products database | The database provides the current UK authorisation record. | It does not verify products outside the authorised supply chain. | 10 August 2026 |
| WADA 2026 Prohibited List | Gonadotrophin-releasing factors are prohibited in male athletes. | Sport status is separate from diagnostic validity. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Gonadorelin for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
The UK Summary of Product Characteristics defines gonadorelin’s diagnostic indication, administration setting, interpretation and safety information. This regulatory evidence directly supports the test within its labelled context. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Gonadorelin authorised in the UK for this use?
A gonadorelin diagnostic medicine is authorised in the UK for specified specialist testing. The label and clinical setting define the claim; it is not a general wellness product. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Gonadorelin is a gonadotrophin-releasing factor and is prohibited in male athletes at all times under WADA S2. Athletes require current sport-specific advice. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
A material change to the UK label, diagnostic guideline, assay interpretation or regulator safety information. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation